查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018444

新冠肺炎臨床試驗市場：全球市場預測（依試驗階段、疾病適應症、申辦類型、試驗設計及資金來源分類）－2026年至2032年

COVID-19 Clinical Trials Market by Trial Phase, Disease Indication, Sponsor Type, Trial Design, Funding Source - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，COVID-19 臨床試驗市場價值將達到 77.4 億美元，到 2026 年將成長至 88.3 億美元，到 2032 年將達到 197.8 億美元，複合年成長率為 14.33%。

主要市場統計數據
基準年 2025 77.4億美元
預計年份：2026年 88.3億美元
預測年份 2032 197.8億美元
複合年成長率 (%) 14.33%

在疫情帶來的臨床研究實踐、病患參與和監管調整的變化背景下，研究實施模式進行了重組。

全球呼吸道疾病大流行導致臨床研究實踐、管治和相關人員期望快速變化。臨床實驗原本遵循既定的節奏，如今卻面臨調整終點指標、受試者招募策略和營運模式的迫切壓力。因此，為了滿足縮短的試驗週期和更高的安全要求，同時保持科學嚴謹性，臨床研究生態系統在臨床實驗推出、病人參與和資料收集等各個方面都經歷了快速重組。

確定整個臨床試驗生態系統中的關鍵結構和程序變化，這些變化將緊急應變策略轉變為永續的能力。

臨床試驗環境已發生變革性轉變，重新定義了研究的設計、實施和監管方式。首先，技術整合已遠遠超越了單一工具的範疇，發展成為一個支援遠端訪視、即時分析和可互通電子健康記錄 (EHR) 整合的統一平台。因此，試驗團隊現在依賴持續的數據流和自動化的品質檢查，在保持監管的同時，減輕了現場工作人員的負擔。其次，以病人為中心的理念已從理論框架發展成為實踐的必然選擇，促進了更靈活的合格標準、居家干預和有針對性的推廣，以提高受試者的多樣性和保留率。

本檢驗了關稅環境的變化如何影響臨床試驗的採購、供應鏈韌性和營運計畫。

廣泛的地緣政治和貿易變化，包括影響藥品原料和醫療用品的關稅政策，為臨床實驗申辦方和服務供應商帶來了新的營運考量。進口耗材和專用設備的關稅提高改變了籌資策略，促使各機構重新評估供應商多元化、庫存持有和離岸生產方案。因此，由於申辦方尋求降低關稅相關成本和供應波動風險，這些調整影響了試驗啟動計畫和日常營運準備。

我們分析試驗階段、目標疾病、申辦者類型、試驗設計和資金籌措結構如何帶來獨特的營運挑戰和機會。

策略性細分揭示了不同試驗類型和申辦者背景所帶來的不同營運需求和機會。根據試驗階段，市場研究分為 I 期、II 期、III 期和 IV 期，每個階段都需要獨特的安全性監測、資料收集強度和受試者招募管道。早期研究通常優先考慮密集的藥物動力學評估和受控環境，而後期試驗則強調更廣泛的受試者多樣性和可操作的終點指標。根據疾病適應症，市場研究分為循環系統、胃腸道、神經系統和呼吸系統疾病。這會影響終點指標的選擇、生物標記的使用以及實施機構的專業技術要求。例如，呼吸系統疾病研究可以利用遠端肺功能測定，而神經系統疾病研究通常需要專門的影像學檢查和神經認知功能評估。

本分析探討了世界各地不同的法規結構、臨床實驗的專業知識和基礎設施如何影響臨床試驗的可行性和營運策略。

區域趨勢持續影響全球的臨床試驗可行性、監管合作和受試者招募策略。在美洲，完善的臨床研究基礎設施和多元化的患者群體為複雜的跨國臨床試驗提供了支持，但相關人員必須應對不同的法規結構和區域支付方情況。相較之下，歐洲、中東和非洲（EMEA）地區的監管成熟度、臨床能力和患者准入模式各不相同，需要製定個人化的監管策略和量身定做的研究中心選擇方案，以確保數據品質的一致性。同時，亞太地區的臨床試驗能力正在迅速提升，臨床研究人才日益增多，部分地區的監管協調也在推進，但申辦方常常面臨臨床實驗研究者經驗的差異和區域特有的後勤限制。

這凸顯了贊助策略、合約研究的演變以及機構間夥伴關係如何重塑能力組合和合作夥伴選擇標準。

企業行為和策略定位對臨床研究生態系內的試驗執行、夥伴關係和創新成果傳播有顯著影響。大型製藥企業正日益將分散式要素和數位化終點納入其研發項目，而生物技術公司則通常開展以生物標記主導的密集型試驗，這需要與專業實驗室和敏捷的生產能力建立合作關係。合約研究組織 (CRO) 透過對技術平台、病人參與服務和區域覆蓋範圍的定向投資，不斷提升自身能力，以支持跨不同申辦方的端到端試驗執行。

臨床試驗領導者面臨的實際策略挑戰，包括建立具有韌性的營運、提高參與者參與度以及降低供應鏈和監管風險。

產業領導者需要採取切實可行且具有前瞻性的措施，以確保臨床實驗的連續性、加快研發進度並改善受試者體驗。首先，他們必須策略性地投資於可互通的技術平台，這些平台能夠支援遠端資料收集、集中監控和安全資料共用，同時確保符合適用的隱私和資料保護框架。這種基礎能力能夠提升營運的擴充性，並降低對單一故障點的依賴。其次，他們必須與多元化的供應商建立合作關係，並探索近岸生產方案，以減輕貿易中斷的影響，並確保關鍵耗材和專用設備的穩定供應。

本報告概述了一種透明的調查方法，該方法結合了相關人員訪談、文獻整合和營運分析，以確保獲得可操作和可靠的見解。

本研究整合了對主要相關人員的訪談、對二手文獻的回顧以及跨部門營運分析，以確保調查方法的穩健性和透明度。關鍵的輸入包括與臨床試驗贊助者、臨床營運經理、監管專家和供應鏈經理的討論，以收集關於營運挑戰和適應策略的多元觀點。這些定性研究結果與公開的監管指南、關於分散式方法的同行評審文獻以及近期臨床實驗試驗實踐的案例研究研究進行了交叉比對，檢驗新出現的主題並識別一致的模式。

我們得出結論，敏捷性、以受試者為中心的實踐和強大的供應策略是面向未來的臨床研究計畫的重要基礎。

現有證據支持一項基本結論：營運彈性、以患者為中心的設計以及供應鏈韌性是後疫情時代有效臨床研究的三大支柱。整合靈活訪視模式、強大的數位基礎設施和多元化籌資策略的臨床試驗展現出更高的連續性和更相關人員協作。此外，適應性強的監管協作和跨部門合作能夠加速學習，並促進有效營運創新快速應用。鑑於這些現實情況，領導者需要重新調整投資方向，以增強在不斷變化的環境中減少摩擦、縮短決策週期和維持資料品質的能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依試驗階段分類的 COVID-19 臨床試驗市場

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第9章：新冠肺炎臨床試驗市場：依疾病適應症分類

  • 心血管系統
  • 消化器官系統
  • 神經系統
  • 呼吸系統

第10章：以申辦單位類型分類的 COVID-19 臨床試驗市場

  • 學術機構
  • 生物技術
  • CRO
  • 政府
  • 製藥公司

第11章 新冠肺炎臨床試驗市場（依試驗設計分類）

  • 自適應
  • 雙盲
  • 開放標籤
  • 隨機化

第12章：新冠肺炎臨床試驗市場（依資金來源分類）

  • 混合物
  • 私人的
  • 民眾

第13章：新冠肺炎臨床試驗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：COVID-19臨床試驗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：新冠肺炎臨床試驗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國新冠肺炎臨床試驗市場

第17章：中國的COVID-19臨床試驗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca PLC
  • BioNTech SE
  • CureVac NV
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ICON plc
  • IQVIA Holdings Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sinopharm Group Co., Ltd.
  • Sinovac Biotech Ltd.
  • Syneos Health, Inc.
Product Code: MRR-0360AB17E232

The COVID-19 Clinical Trials Market was valued at USD 7.74 billion in 2025 and is projected to grow to USD 8.83 billion in 2026, with a CAGR of 14.33%, reaching USD 19.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.74 billion
Estimated Year [2026] USD 8.83 billion
Forecast Year [2032] USD 19.78 billion
CAGR (%) 14.33%

Contextualizing the pandemic-driven evolution in clinical research operations, patient engagement, and regulatory adaptations that reshaped study delivery models

The onset of the global respiratory pandemic precipitated an accelerated evolution in clinical research practice, governance, and stakeholder expectations. Trials that once followed long-established rhythms encountered urgent pressures to adapt endpoints, recruitment strategies, and operational delivery models. As a consequence, the clinical research ecosystem undertook rapid reconfiguration across trial setup, patient engagement, and data capture to preserve scientific rigor while meeting compressed timelines and heightened safety demands.

Over time, these adaptations matured into durable practices that extend beyond the immediate crisis. Remote monitoring, electronic consent, and decentralized visit schedules migrated from experimental pilot programs into accepted components of study protocols. At the same time, regulatory authorities issued temporary flexibilities that clarified acceptable approaches to remote assessments and data integrity. As a result, sponsors and clinical operations teams now navigate a hybridized landscape where virtual and site-based modalities coexist, patient-centric approaches shape enrollment, and cross-functional coordination underpins rapid trial execution. This introduction frames the subsequent analysis by emphasizing how short-term exigencies became catalysts for long-term structural change in clinical research.

Identifying the major structural and procedural shifts that converted emergency adaptations into enduring capabilities across clinical trial ecosystems

The landscape of clinical trials underwent transformative shifts that redefined how studies are designed, executed, and overseen. First, technological integration expanded well beyond isolated tools into coherent platforms that support remote visits, real-time analytics, and interoperable electronic health record linkages. Consequently, trial teams now rely on continuous data streams and automated quality checks to maintain oversight while reducing on-site burden. Second, patient-centric approaches advanced from theoretical frameworks to operational imperatives, prompting more flexible eligibility criteria, home-based interventions, and targeted outreach to improve diversity and retention.

Furthermore, partnerships between academic centers, industry sponsors, and contract research organizations deepened, producing novel hybrid models for resource sharing and risk allocation. Regulatory agencies responded with guidance that balanced methodological rigor and practical flexibility, which in turn catalyzed the adoption of adaptive trial designs and pragmatic endpoints. In addition, supply chain and logistics capabilities strengthened to support decentralized distribution of investigational products and remote sampling. Taken together, these shifts have produced a more resilient and adaptable trial ecosystem that can respond more rapidly to emergent public health needs while maintaining scientific integrity and ethical oversight.

Examining how evolving tariff environments reshaped procurement, supply chain resilience, and operational planning for clinical trial execution

Changes in the broader geopolitical and trade environment, including tariff policies affecting pharmaceutical inputs and medical supplies, created new operational considerations for trial sponsors and service providers. Increased levies on imported consumables and specialized equipment altered procurement strategies and prompted organizations to reassess supplier diversification, inventory holdings, and nearshore production options. In turn, these adjustments influenced timelines for study start-up and routine operational readiness, as sponsors sought to mitigate exposure to tariff-driven cost and availability volatility.

In response, clinical trial stakeholders adopted several tactical measures. Procurement teams established multi-tiered supplier networks and emphasized contracts with flexible terms to manage delivery risk. Operational planners integrated longer lead times into supply chain schedules and prioritized local sourcing where feasible to reduce cross-border dependencies. Meanwhile, finance and legal functions collaborated more closely to model tariff impacts on contractual obligations and to incorporate contingency clauses. Collectively, these measures enhanced program resilience by aligning procurement and operational strategies with an increasingly complex trade environment, thereby reducing the likelihood that external tariff shifts will derail trial continuity.

Unpacking how trial phase, disease focus, sponsor archetype, design choices, and funding structures create distinct operational imperatives and opportunities

Strategic segmentation illuminates differing operational needs and opportunities across study types and sponsor profiles. Based on Trial Phase, market is studied across Phase I, Phase Ii, Phase Iii, and Phase Iv, each demanding distinct safety oversight, data collection intensity, and recruitment channels. Early phase work typically prioritizes intensive pharmacokinetic assessment and controlled environments, whereas later phase trials emphasize broader population diversity and pragmatic endpoints. Based on Disease Indication, market is studied across Cardiovascular, Gastrointestinal, Neurological, and Respiratory, which influences endpoint selection, biomarker use, and site expertise requirements; for example, respiratory studies may leverage remote spirometry, while neurological programs often require specialized imaging and neurocognitive assessments.

Moreover, sponsor type drives resource allocation and governance approaches. Based on Sponsor Type, market is studied across Academic, Biotechnology, Cro, Government, and Pharmaceutical, which produces variation in risk tolerance, access to patient networks, and capital availability. Trial design further differentiates operational complexity; Based on Trial Design, market is studied across Adaptive, Double Blind, Open Label, and Randomized approaches, with adaptive protocols necessitating advanced statistical frameworks and real-time decision gates. Finally, funding arrangements influence procurement and oversight intensity; Based on Funding Source, market is studied across Mixed, Private, and Public funding models, which affect reporting obligations, stakeholder alignment, and timelines. Integrating these segmentation lenses enables tailored operational strategies that align resources with the unique demands and success factors of each trial cohort.

Analyzing how differential regulatory frameworks, investigator expertise, and infrastructure across global regions influence study feasibility and operational strategy

Regional dynamics continue to shape trial feasibility, regulatory interactions, and patient recruitment strategies across global portfolios. In the Americas, established clinical research infrastructures and diverse patient populations support complex multinational studies, yet stakeholders must navigate heterogeneous regulatory frameworks and localized payer considerations. In contrast, Europe, Middle East & Africa exhibit a mosaic of regulatory maturity, varying clinical capacity, and differing patient access patterns that require bespoke regulatory strategies and tailored site selection to ensure consistent data quality. Meanwhile, Asia-Pacific offers rapidly expanding trial capacity, growing clinical research talent, and increasing regulatory harmonization in some jurisdictions, though sponsors often contend with variable investigator experience and localized logistical constraints.

Given these differences, successful regional strategies combine centralized program governance with localized operational autonomy. For example, harmonized protocol templates and common data standards can be implemented centrally, while country teams manage recruitment tactics, regulatory submissions, and site training to reflect local practice. Furthermore, cross-regional learning accelerates capability building; insights from high-volume sites in one geography can inform process improvements elsewhere. Ultimately, a regionally calibrated approach increases the chances of efficient enrollment, robust data capture, and timely regulatory engagement while respecting local context and patient needs.

Highlighting how sponsor strategies, contract research evolution, and institutional partnerships are reshaping capability sets and partner selection criteria

Company behavior and strategic positioning have a material effect on trial execution, partnerships, and innovation diffusion within the clinical research ecosystem. Leading pharmaceutical sponsors increasingly embed decentralized elements and digital endpoints within development programs, while biotechnology firms often pursue focused, biomarker-driven trials that require specialized laboratory partnerships and nimble manufacturing arrangements. Contract research organizations continue to expand capabilities through targeted investments in technology platforms, patient engagement services, and regional footprint expansion to support end-to-end study delivery for a diverse sponsor base.

Academic institutions and government-sponsored programs play complementary roles by advancing methodological innovation, enabling investigator-initiated studies, and supporting large pragmatic trials. Collaboration between private and public actors has produced efficient models for sharing data and operational resources, which accelerates learning and reduces duplication. In addition, a subset of companies distinguishes itself through vertically integrated service offerings that combine site networks, patient recruitment expertise, and regulatory consulting, thereby lowering trial friction for complex protocols. Observing these company-level dynamics helps stakeholders identify potential partners, anticipate capability gaps, and prioritize investments that align with operational needs and strategic goals.

Practical strategic imperatives for clinical trial leaders to build resilient operations, enhance participant engagement, and mitigate supply chain and regulatory risks

Industry leaders must adopt pragmatic, forward-looking actions to maintain trial continuity, accelerate development timelines, and enhance participant experience. First, invest strategically in interoperable technology platforms that support remote data capture, centralized monitoring, and secure data sharing while ensuring compliance with applicable privacy and data protection frameworks. This foundational capability enables operational scalability and reduces reliance on single points of failure. Second, cultivate diversified supplier relationships and nearshore manufacturing options to mitigate exposure to trade-related disruptions and to maintain steady access to critical consumables and specialized equipment.

Third, embed patient-centric practices into protocol design and site execution to improve enrollment diversity and retention; this includes flexible visit windows, home health capabilities, and culturally informed recruitment strategies. Fourth, strengthen cross-functional governance that integrates clinical operations, regulatory affairs, procurement, and legal teams to anticipate and respond rapidly to external shocks. Finally, prioritize targeted partnerships with contract research organizations and specialized vendors that demonstrate proven experience in decentralized methods and therapeutic area expertise. By implementing these recommendations, organizations can improve operational resilience and position their development programs for sustained success in a dynamic environment.

Outlining a transparent research methodology combining stakeholder interviews, literature integration, and operational analysis to ensure actionable and reliable insights

This research synthesizes primary stakeholder interviews, secondary literature review, and cross-functional operational analyses to ensure a robust and transparent methodological foundation. Primary inputs included discussions with study sponsors, clinical operations leaders, regulatory specialists, and supply chain managers to capture diverse perspectives on operational challenges and adaptive strategies. These qualitative insights were triangulated with publicly available regulatory guidance, peer-reviewed literature on decentralized methods, and documented case studies of recent trial implementations to validate emerging themes and identify consistent patterns.

Analytical processes emphasized methodological transparency and reproducibility. The study applied thematic coding to interview transcripts, comparative process mapping to operational workflows, and scenario analysis to evaluate the implications of trade and regulatory variants. Throughout, the methodology prioritized methodological rigor, ethical considerations, and data integrity, with an explicit focus on operational applicability rather than commercial metrics. Limitations are acknowledged where stakeholder representation was uneven across geographies or therapeutic areas; nevertheless, cross-validation techniques and convergence of multiple evidence sources increased confidence in the findings and recommendations presented.

Concluding that agility, participant-centered practices, and resilient supply strategies constitute the essential foundation for future-ready clinical research programs

The accumulated evidence underscores a fundamental conclusion: operational agility, patient-centric design, and supply chain resilience are the pillars of effective clinical research in the post-pandemic era. Trials that integrate flexible visit models, robust digital infrastructure, and diversified procurement strategies demonstrate greater continuity and stakeholder alignment. Moreover, adaptive regulatory engagement and cross-sector collaborations accelerate learning and facilitate the rapid adoption of efficacious operational innovations. These realities call for leaders to reorient investments toward capabilities that lower friction, shorten decision cycles, and preserve data quality under changing conditions.

Looking ahead, organizations that invest in people, processes, and platforms-while maintaining an explicit focus on participant welfare and ethical standards-will be best positioned to conduct efficient, generalizable, and impactful clinical research. The path forward requires both strategic discipline and tactical flexibility, with an emphasis on continuous improvement and evidence-based operational refinement. In sum, the industry has an opportunity to institutionalize the most effective pandemic-era innovations and thereby improve the speed, inclusivity, and resilience of clinical development programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Clinical Trials Market, by Trial Phase

  • 8.1. Phase I
  • 8.2. Phase Ii
  • 8.3. Phase Iii
  • 8.4. Phase Iv

9. COVID-19 Clinical Trials Market, by Disease Indication

  • 9.1. Cardiovascular
  • 9.2. Gastrointestinal
  • 9.3. Neurological
  • 9.4. Respiratory

10. COVID-19 Clinical Trials Market, by Sponsor Type

  • 10.1. Academic
  • 10.2. Biotechnology
  • 10.3. Cro
  • 10.4. Government
  • 10.5. Pharmaceutical

11. COVID-19 Clinical Trials Market, by Trial Design

  • 11.1. Adaptive
  • 11.2. Double Blind
  • 11.3. Open Label
  • 11.4. Randomized

12. COVID-19 Clinical Trials Market, by Funding Source

  • 12.1. Mixed
  • 12.2. Private
  • 12.3. Public

13. COVID-19 Clinical Trials Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. COVID-19 Clinical Trials Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. COVID-19 Clinical Trials Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States COVID-19 Clinical Trials Market

17. China COVID-19 Clinical Trials Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AstraZeneca PLC
  • 18.6. BioNTech SE
  • 18.7. CureVac N.V.
  • 18.8. Eli Lilly and Company
  • 18.9. Gilead Sciences, Inc.
  • 18.10. GlaxoSmithKline plc
  • 18.11. ICON plc
  • 18.12. IQVIA Holdings Inc.
  • 18.13. Johnson & Johnson
  • 18.14. Merck & Co., Inc.
  • 18.15. Moderna, Inc.
  • 18.16. Novavax, Inc.
  • 18.17. Pfizer Inc.
  • 18.18. Regeneron Pharmaceuticals, Inc.
  • 18.19. Roche Holding AG
  • 18.20. Sanofi S.A.
  • 18.21. Sinopharm Group Co., Ltd.
  • 18.22. Sinovac Biotech Ltd.
  • 18.23. Syneos Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, 2020-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COVID-19 CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, 2020-2032 (USD MILLION)
  • FIGURE 13. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, 2020-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, 2020-2032 (USD MILLION)
  • TABLE 2. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 3. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY ACADEMIC, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY ACADEMIC, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY CRO, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY CRO, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY CRO, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY GOVERNMENT, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY GOVERNMENT, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY GOVERNMENT, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY DOUBLE BLIND, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY DOUBLE BLIND, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY DOUBLE BLIND, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY OPEN LABEL, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY OPEN LABEL, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY OPEN LABEL, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY MIXED, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY MIXED, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY MIXED, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRIVATE, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRIVATE, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRIVATE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 64. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PUBLIC, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 65. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PUBLIC, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 66. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PUBLIC, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 67. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY REGION, 2020-2032 (USD MILLION)
  • TABLE 68. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2020-2032 (USD MILLION)
  • TABLE 69. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 70. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 71. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 72. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 73. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2020-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 92. EUROPE COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 93. EUROPE COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 94. EUROPE COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 95. EUROPE COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 96. EUROPE COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 97. EUROPE COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 104. AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 105. AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 106. AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 107. AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 108. AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 109. AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 116. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY GROUP, 2020-2032 (USD MILLION)
  • TABLE 117. ASEAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 118. ASEAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 119. ASEAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 120. ASEAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 121. ASEAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 122. ASEAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 123. GCC COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 124. GCC COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 125. GCC COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 126. GCC COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 127. GCC COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 128. GCC COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 135. BRICS COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 136. BRICS COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 137. BRICS COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 138. BRICS COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 139. BRICS COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 140. BRICS COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 141. G7 COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 142. G7 COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 143. G7 COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 144. G7 COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 145. G7 COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 146. G7 COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 147. NATO COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 148. NATO COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 149. NATO COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 150. NATO COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 151. NATO COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 152. NATO COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 153. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2020-2032 (USD MILLION)
  • TABLE 154. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, 2020-2032 (USD MILLION)
  • TABLE 155. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 156. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 157. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 158. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 159. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)
  • TABLE 160. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, 2020-2032 (USD MILLION)
  • TABLE 161. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2020-2032 (USD MILLION)
  • TABLE 162. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY DISEASE INDICATION, 2020-2032 (USD MILLION)
  • TABLE 163. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2020-2032 (USD MILLION)
  • TABLE 164. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2020-2032 (USD MILLION)
  • TABLE 165. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY FUNDING SOURCE, 2020-2032 (USD MILLION)